Selinexor Dosage
Medically reviewed by Drugs.com. Last updated on Aug 21, 2023.
Applies to the following strengths: 20 mg; 40 mg; 50 mg; 60 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Multiple Myeloma
IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE (SVd):
100 mg orally once weekly on Day 1 of each week until disease progression or unacceptable toxicity in combination with bortezomib 1.3 mg/m2 subcutaneously once weekly on Day 1 of each week for 4 weeks followed by 1 week off; dexamethasone 20 mg orally twice weekly on Days 1 and 2 of each week
IN COMBINATION WITH DEXAMETHASONE:
80 mg orally on Day 1 and 3 of each week until disease progression or unacceptable toxicity in combination with dexamethasone 20 mg orally with each dose of selinexor on Days 1 and 3 of each week
Comments:
- For additional information regarding the administration of bortezomib and dexamethasone, refer to its prescribing information.
- Consider IV hydration for patients at risk of dehydration.
- Provide prophylactic concomitant treatment with a 5-HT3 antagonist and/or other anti-nausea agents prior to and during therapy.
Uses:
- In combination with bortezomib and dexamethasone for patients with multiple myeloma who have received at least 1 prior therapy
- In combination with dexamethasone for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody
Usual Adult Dose for Lymphoma
60 mg orally on Day 1 and 3 of each week until disease progression or unacceptable toxicity
Comments:
- Consider IV hydration for patients at risk of dehydration.
- Provide prophylactic concomitant treatment with a 5-HT3 antagonist and/or other anti-nausea agents prior to and during therapy.
Use: For the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
DOSE REDUCTION FOR ADVERSE REACTIONS:
Multiple Myeloma in combination with bortezomib and dexamethasone (SVd):
- Starting dose: 100 mg once a week
- First reduction: 80 mg once a week
- Second reduction: 60 mg once a week
- Third reduction: 40 mg once a week
- Fourth reduction: Permanently discontinue therapy.
- Starting dose: 80 mg on Days 1 and 3 of each week (160 mg total per week)
- First reduction: 100 mg once a week
- Second reduction: 80 mg once a week
- Third reduction: 60 mg once a week
- Fourth reduction: Permanently discontinue therapy.
- Starting dose: 60 mg on Day 1 and 3 of each week (120 mg total per week)
- First reduction: 40 mg on Days 1 and 3 of each week (80 mg total per week)
- Second reduction: 60 mg once a week
- Third reduction: 40 mg once a week
- Fourth reduction: Permanently discontinue therapy.
MULTIPLE MYELOMA DOSE MODIFICATIONS:
HEMATOLOGIC ADVERSE REACTIONS:
THROMBOCYTOPENIA:
- Platelet count 25,000 to less than 75,000/mcL: For any occurrence reduce the dose by 1 dose level.
- Platelet count 25,000 to less than 75,000/mcL with concurrent bleeding: For any occurrence interrupt therapy; restart at 1 dose level lower after bleeding has resolved; administer platelet transfusions per guidelines.
- Platelet count less than 25,000/mcL: For any occurrence interrupt therapy; monitor until platelet count returns to at least 50,000/mcL; restart at 1 dose level lower.
- Absolute neutrophil count 0.5 to 1 x 10(9)/L without fever: For any occurrence reduce the dose by 1 dose level.
- Absolute neutrophil count less than 0.5 x 10(9)/L OR febrile neutropenia: For any occurrence interrupt therapy; monitor until neutrophil count returns to 1 x 10(9)/L or higher; restart at 1 dose level lower.
- Hemoglobin less than 8 g/dL: For any occurrence reduce the dose by 1 dose level; administer blood transfusions per guidelines.
- Life-threatening consequences: For any occurrence interrupt therapy; monitor hemoglobin until levels return to 8 g/dL or higher; restart therapy at 1 dose level lower; administer blood transfusions per guidelines.
DIFFUSE LARGE B-CELL LYMPHOMA DOSE MODIFICATIONS:
HEMATOLOGIC ADVERSE REACTIONS:
THROMBOCYTOPENIA:
- Platelet count 50,000 to less than 75,000/mcL: For any occurrence interrupt one dose of this drug; restart this drug at the same dose level.
- Platelet count 25,000 to less than 50,000/mcL without bleeding: For the first occurrence, interrupt therapy; monitor until platelet count returns to at least 50,000/mcL; reduce by one dose level.
- Platelet count 25,000/mcL to less than 50,000/mcL with concurrent bleeding: For any occurrence interrupt therapy; monitor until platelet count returns to at least 50,000/mcL; restart at 1 dose level lower after bleeding resolves; administer platelet transfusions per guidelines.
- Platelet count less than 25,000/mcL: For any occurrence interrupt therapy; monitor until platelet count returns to at least 50,000/mcL; restart at 1 dose level lower; administer platelet transfusions per guidelines.
- Absolute neutrophil count 0.5 to less than 1 x 10(9)/L without fever: For the first occurrence interrupt therapy; monitor until neutrophil counts return to 1 x 10(9)/L or higher; restart at the same dose level. For a recurrence interrupt therapy; monitor until neutrophil counts return to 1 x 10(9) or higher; administer growth factors per guidelines; restart at one dose level lower.
- Absolute neutrophil count less than 0.5 x 10(9)/L OR febrile neutropenia: For any occurrence interrupt therapy; monitor until neutrophil count returns to 1 x 10(9)/L; restart at 1 dose level lower.
- Hemoglobin less than 8 g/dL: For any occurrence reduce the dose by 1 dose level; administer blood transfusions per guidelines.
- Life-threatening consequences: For any occurrence interrupt therapy; monitor hemoglobin until levels return to 8 g/dL or higher; restart therapy at 1 dose level lower; administer blood transfusions per guidelines.
DOSE MODIFICATIONS FOR NONHEMATOLOGIC ADVERSE REACTIONS:
NAUSEA AND VOMITING:
- Grade 1 or 2 nausea (oral intake decreased without significant weight loss, dehydration, or malnutrition) OR Grade 1 or 2 vomiting (5 or fewer episodes per day): For any occurrence continue therapy and initiate additional anti-nausea medications.
- Grade 3 nausea (inadequate oral caloric or fluid intake) OR Grade 3 or higher vomiting (6 or more episodes per day): For any occurrence interrupt therapy; monitor until nausea or vomiting has resolved to Grade 2 or lower or baseline; initiate additional anti-nausea medications; restart therapy at 1 dose level lower.
- Grade 2 (increase of 4 to 6 stools per day over baseline): For first occurrence continue therapy and institute supportive care; for second and subsequent occurrences reduce dose by 1 dose level and institute supportive care.
- Grade 3 or higher (increase of 7 stools or more per day over baseline; hospitalization indicated): For any occurrence interrupt therapy and institute supportive care; monitor until diarrhea resolves to Grade 2 or lower; restart therapy at 1 dose level lower.
- Weight loss of 10% to less than 20% OR anorexia associated with significant weight loss or malnutrition: For any occurrence interrupt therapy and institute supportive care; monitor until weight returns to more than 90% of baseline weight; restart therapy at 1 dose level lower.
- Sodium level 130 mmol/L or less: For any occurrence interrupt therapy and provide supportive care; monitor until sodium levels return to 130 mmol/L or higher; restart therapy at 1 dose level lower.
- Grade 2 lasting longer than 7 days OR Grade 3: For any occurrence interrupt therapy; monitor until fatigue resolves to Grade 1 or baseline; restart therapy at 1 dose level lower.
- Grade 2 excluding cataract: For any occurrence perform ophthalmologic evaluation; interrupt therapy and provide supportive care; monitor until ocular symptoms resolve to Grade 1 or baseline; restart therapy at 1 dose level lower.
- Grade 3 or greater excluding cataract: For any occurrence permanently discontinue therapy; perform ophthalmologic evaluation.
- Grade 3 or 4 (life-threatening): For any occurrence interrupt therapy; monitor until resolved to Grade 2 or lower; restart therapy at 1 dose level lower.
Precautions
CONTRAINDICATIONS:
- None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- This drug should be taken at the same time each day.
- Swallow tablets whole with water; do not break, chew, crush, or divide the tablet.
- If a dose is missed or delayed, take the next dose at the next regularly scheduled time.
- If a patient vomits a dose, the patient should not repeat the dose and should take the next dose on the next regularly scheduled day.
Storage requirements:
- Store at or below 30C (86F).
Monitoring:
- Monitor complete blood count (CBC) with differential, standard blood chemistries, body weight, nutritional status, and volume status at baseline and during therapy as indicated. Monitor more frequently during the first 3 months.
Patient advice:
- Maintain adequate fluid and caloric intake throughout therapy.
More about selinexor
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- Drug class: miscellaneous antineoplastics
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.